Dr. Joy Kong explains why BPC-157, a peptide that heals tissue by stimulating blood vessel growth, could theoretically accelerate undiagnosed cancers. No direct evidence exists, but the concern is real: tumors exploit the same blood-supply mechanism. Long-term human safety data is missing.
The second issue is the theoretical cancer risk. Let's think logically about how BPC-157 works. It aggressively promotes angiogenesis, which is the growth of new blood vessels that will promote cellular proliferation, right, to help heal the tissue. But tumors use the exact mechanism to survive and grow. They rely on angiogenesis. So while BPC-157 hasn't been shown to cause cancer, scientists are worried that if someone has an existing Undiagnosed early-stage cancer, maybe inducing a powerful angiogenic agent could inadvertently feed the tumor, thus accelerating its growth. But we don't really have long-term human safety trials, so we don't know exactly where this risk is at. Where do we go from here? What's the future of BPC-157? We're moving away from the Wild West era of unregulated internet biohacking and moving toward more legitimate targeted medical therapies.
